Irinotecan25,40,41,j,n Days 1 and 8: Irinotecan 125mg/m 2 IV over 30–90 minutes
The aim of this
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of
2004 (1·9–7·2) in the capecitabine group
Caution: upfront 20% dose reduction for irinotecan and capecitabine (with the dose of capecitabine rounded down to the nearest 500 mg) should be considered in patients at risk of severe diarrhoea (e
5 mg/kg IV
5 mg/kg IV every 3 weeks doses 2001-02-02: Initial market authorization as Xeloda
No information available
Irinotecan With LV5FU2 (DeGramont) Schedule As a result of the difficulties with the toxicities from the traditional IFL schedule and the approval of oxaliplatin/ 5-FU/leucovorin as second-line chemotherapy, infusional schedules have garnered greater attention and acceptance in the United States
However, these
The safety profile of capecitabine–irinotecan plus bevacizumab administered every 2 weeks was comparable with reports from other phase II studies
Listing a study does not mean it has been evaluated by the U
The use of irinotecan based chemotherapy may be more feasible than oxaliplatin based chemotherapy, and more clinical trials on maintenance therapy are
5x109/L or greater
December 2012 #3
Both, CapOx-bevacizumab and mCapIri-bevacizumab, show promising activity and an excellent toxic effect profile
Background: To compare the efficacy and safety of CAPIRI+bevacizumab (Bev) in comparison with FOLFIRI+Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC)
Acute cholinergic syndrome, diarrhoea (may be delayed), myelosuppression